darzalex
Potential blockbuster AZ immunotherapy secures FDA approval
May 2, 2017Manufacturing and Production, Sales and Marketing AstraZeneca, bladder cancer, darzalex
The FDA has granted accelerated approval to AstraZeneca’s (AZ) immunotherapy therapy Imfinzi (durvalumab) for the treatment of locally advanced or …
Janssen scores EU approval for blood cancer drug Darzalex
May 2, 2017Manufacturing and Production, Sales and Marketing Europe, European Commission, Janssen, darzalex
Janssen has announced that its CD38-directed monoclonal antibody Darzalex (daratumumab) has expanded its indication with a thumbs-up from the European …
EMA recommends expanded indication for Janssen multiple myeloma drug
February 27, 2017Manufacturing and Production, Research and Development, Sales and Marketing Janssen, darzalex
The European Medicines Agency’s Committee for Medicinal Products for Human Use has given its positive opinion for the use of …
SMC rejects Janssen’s multiple myeloma treatment Darzalex
January 17, 2017Manufacturing and Production, Sales and Marketing Janssen, SMC, darzalex
The Scottish Medicines Consortium (SMC) has decided not to recommend Janssen’s Darzalex (daratumumab) for routine use by NHS Scotland as …
J&J and Genmab’s drug races to second line treatment approval
November 22, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, Johnson & Johnson, darzalex, multiple myeloma
Janssen, a part of Johnson & Johnson, and Genmab have announced that their multiple myeloma drug Darzalex (daratumumab) has been …
Darzalex receives breakthrough designation in multiple myeloma from FDA
July 26, 2016Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …
Genmab receives milestone payment for first Darzalex sale in Europe
May 31, 2016Manufacturing and Production, Sales and Marketing EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales
Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its …
Darzalex meets endpoint in late-stage multiple myeloma trial
May 19, 2016Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial
Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …
Janssen and Genmab sued for patent infringement in US
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement
German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).
Two CHMP nods for Janssen
April 4, 2016Research and Development, Sales and Marketing Xeplion, darzalex, multiple myeloma
The European Commission’s scientific committee has recommended Janssen’s Darzalex (daratumumab) for multiple myeloma and Trevicta (paliperidone palmitate) for maintenance treatment …
Genmab Darzalex success triggers second milestone payment
March 10, 2016Research and Development, Sales and Marketing Genmab, Janssen, daratumumab, darzalex, follicular lymphoma
Genmab says it has reached a $5 million milestone in its daratumumab collaboration with Janssen as a result of success …
Strong cancer trial data for Janssen at ASH 2015
December 8, 2015Research and Development Cancer, Janssen, darzalex, imbruvica, oncology
Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …
